Armata Pharmaceuticals Receives $3.7 Million in Additional Non-Dilutive Funding from U.S. Department of War to Support Advancement of AP-SA02 Phase 3 Development

Go back to Armata Pharmaceuticals Receives $3.7 Million in Additional Non-Dilutive Funding from U.S. Department of War to Support Advancement of AP-SA02 Phase 3 Development
Aurum Resources Corp (NYSE: ARMP) Delayed: 3.06 -0.14 (4.38%)
Previous Close $3.20    52 Week High $2.00 
Open $3.21    52 Week Low $1.50 
Day High $3.21    P/E N/A 
Day Low $2.97    EPS $0.00 
Volume 18,302